DRI Healthcare Acquires Royalty Interest in Viridian Therapeutics Eye Disease Treatments

Paul, Weiss advised DRI Healthcare Trust on the intellectual property and financing aspects of its acquisition of a tiered royalty interest in the U.S. net sales of two treatments for chronic thyroid eye disease from Viridian Therapeutics, Inc., for an aggregate purchase price of up to $300 million. The transaction includes an upfront payment of $55 million and up to $115 million in near-term clinical and regulatory milestone payments. DRI Healthcare is a global leader in providing financing to advance innovation in the life sciences industry.

The Paul, Weiss team was led by partners Jeffrey Osterman and Robert Zochowski.